Get the Stockscreener App
8.54
0.12%
-0.01
Chimerix Inc stock is traded at $8.54, with a volume of 755.34K.
It is down -0.12% in the last 24 hours and down -0.12% over the past month.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.
See More
Previous Close:
$8.55
Open:
$8.55
24h Volume:
755.34K
Relative Volume:
0.20
Market Cap:
$354.50M
Revenue:
$324.00K
Net Income/Loss:
$-82.10M
P/E Ratio:
-9.1828
EPS:
-0.93
Net Cash Flow:
$-69.18M
1W Performance:
+0.00%
1M Performance:
-0.12%
6M Performance:
+893.14%
1Y Performance:
+780.59%
1-Day Range:
$8.54
$8.55
1-Week Range:
$8.54
$8.55
52-Week Range:
$0.75
$8.55
Chimerix Inc Stock (CMRX) Company Profile
Name
Chimerix Inc
Sector
Industry
Phone
919.806.1074
Address
2505 MERIDIAN PARKWAY, SUITE 100, DURHAM, NC
Compare CMRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMRX
Chimerix Inc
|
8.54 | 354.50M | 324.00K | -82.10M | -69.18M | -0.93 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Chimerix Inc Stock (CMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-23-23 | Initiated | Robert W. Baird | Outperform |
| Sep-07-22 | Initiated | CapitalOne | Overweight |
| Apr-29-21 | Initiated | Maxim Group | Buy |
| Apr-23-21 | Resumed | Cowen | Outperform |
| Mar-31-21 | Initiated | Jefferies | Buy |
| Mar-31-21 | Initiated | Wedbush | Outperform |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Feb-02-18 | Initiated | H.C. Wainwright | Buy |
| Aug-09-16 | Reiterated | FBR Capital | Mkt Perform |
| Feb-23-16 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-23-16 | Reiterated | FBR Capital | Mkt Perform |
| Feb-23-16 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Feb-22-16 | Downgrade | Citigroup | Buy → Neutral |
| Dec-29-15 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-15 | Downgrade | FBR Capital | Outperform → Mkt Perform |
| Dec-28-15 | Reiterated | Piper Jaffray | Overweight |
| Dec-17-15 | Initiated | UBS | Buy |
| Oct-05-15 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-03-15 | Initiated | Citigroup | Buy |
| Aug-18-15 | Initiated | FBR Capital | Outperform |
| Aug-06-15 | Reiterated | Brean Capital | Buy |
| May-11-15 | Reiterated | Brean Capital | Buy |
| Mar-04-15 | Initiated | Barclays | Overweight |
| Feb-12-15 | Reiterated | Stifel | Buy |
| Dec-31-14 | Reiterated | Brean Capital | Buy |
| Jul-08-14 | Resumed | Brean Capital | Buy |
View All
Chimerix Inc Stock (CMRX) Latest News
StockNews.com Initiates Coverage on Chimerix (NASDAQ:CMRX) - Defense World
Halper Sadeh LLP, bluebird bio, Inc., Walgreens Boots Alliance, Chimerix, Inc. - Olean Times Herald
Chimerix (NASDAQ:CMRX) Earns Sell Rating from Analysts at StockNews.com - Defense World
Chimerix, Inc. to Host Earnings Call - ACCESS Newswire
Why Chimerix Inc. (CMRX) is Surging in 2025 - Insider Monkey
Investor Network: Chimerix, Inc. to Host Earnings Call - ACCESS Newswire
Geode Capital Management LLC Lowers Stock Holdings in Chimerix, Inc. (NASDAQ:CMRX) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Jazz Pharmaceuticals Acquires Chimerix for $935M - Contract Pharma
Jazz Pharmaceuticals Completes $935 Million Acquisition of Chimerix - marketscreener.com
Jazz Pharmaceuticals acquires Chimerix for $935 million By Investing.com - Investing.com South Africa
Chimerix Terminates Loan and Delists from Nasdaq - TipRanks
Jazz Pharmaceuticals Completes Acquisition of Chimerix | JAZZ St - GuruFocus
Jazz Pharmaceuticals (JAZZ) Completes Acquisition of Chimerix - StreetInsider
Jazz Pharmaceuticals Completes Acquisition of Chimerix - TipRanks
Jazz Pharmaceuticals acquires Chimerix for $935 million - Investing.com
Jazz Pharmaceuticals Completes Acquisition of Chimerix | JAZZ Stock News - GuruFocus
Jazz's $935M Chimerix Buyout Targets First-Ever Treatment for Rare Brain Cancer, FDA Verdict Looms - Stock Titan
Chimerix (NASDAQ:CMRX) Now Covered by StockNews.com - Defense World
Chimerix stock soars to 52-week high, hits $8.54 By Investing.com - Investing.com South Africa
Chimerix stock soars to 52-week high, hits $8.54 - Investing.com
Unlocking Investment Potential Discover the Power of Magical Signals Bullish Signal - AInvest
Top 3 Health Care Stocks That May Crash In Q2 - Benzinga
Chimerix stock soars to 52-week high, hits $8.53 By Investing.com - Investing.com Australia
Chimerix stock soars to 52-week high, hits $8.53 - Investing.com
Is Chimerix Inc. (CMRX) the Best Performing NASDAQ Stock So Far in 2025? - MSN
Jazz Pharmaceuticals, Chimerix HSR waiting period expired on March 31 - MLex
11 Best Performing NASDAQ Stocks So Far in 2025 - Insider Monkey
Exploring US High Growth Tech Stocks In March 2025 - simplywall.st
Chimerix Inc. (NASDAQ:CMRX) Amazing Performance So Far In 2025 - Yahoo
11 Best Performing Stocks So Far In 2025 - Insider Monkey
Jazz strikes the chord with $935m Chimerix acquisition - BioXconomy
Chimerix Reports 2024 Losses Amid Acquisition News - TipRanks
Chimerix earnings missed, revenue fell short of estimates By Investing.com - Investing.com Canada
Chimerix Inc Reports Q4 2024 EPS of -$0.25, Beating Estimates; R - GuruFocus.com
The buildup to Chimerix's $935M exit to Jazz, with more than half a dozen parties intrigued - Endpoints News
Chimerix: Q4 Earnings Snapshot - mySA
Chimerix Inc. (CMRX) reports earnings - Quartz
CHIMERIX INC SEC 10-K Report - TradingView
Chimerix Reports Fourth Quarter and Year End 2024 Financial Results - The Manila Times
Chimerix Inc Stock (CMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):